Deals In Depth: November 2016
Executive Summary
In the largest single-territory deal (worth $434 million) by a South Korean pharmaco, Kolon Life Science licensed Mitsubishi Tanabe Japanese rights to an osteoarthritis gene therapy; Allergan continued its dealmaking spree, paying up to $1 billion for Alzheimer's company Chase. Biopharma financing rebounded thanks to Samsung BioLogics' record-breaking IPO.
You may also be interested in...
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.